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Evaluating Estradiol as a Novel Therapy for Dry Age-
related Macular Degeneration/Geographic Atrophy 
 
Daniel H Lee, Paula S Fukuhara, MC Kenney 
PURPOSE: 
Age-related macular degeneration (AMD) is 
the most common cause of irreversible 
vision loss in the elderly population in the 
United States and is more prevalent in post-
menopausal females than age-matched 
males. There are no current FDA-approved 
therapies for dry AMD, which composes 80-
90% of all AMD cases. Late stage dry AMD 
(geographic atrophy) is characterized by 
extensive loss of the retinal pigment 
epithelium (RPE) along with degeneration 
of the photoreceptors, which cause 
significant central vision loss. AMD is 
characterized by drusen, which are 
extracellular deposits located beneath the 
retina. Drusen contain proteins associated 
with the process of inflammation such as 
activated complement proteins, fragments of 
the membrane attack complex, vitronectin, 
cholesterol, C-reactive protein, and amyloid-
β. Amyloid-β is a cytotoxic protein 
associated with various neurodegenerative 
diseases and is commonly found in plaques 
of Alzheimer’s disease. 
Based on these findings, we hypothesized 
that estradiol may have protective effects 
against the cytotoxic properties of amyloid-b 
in RPE cells in vitro. 
METHODS: 
ARPE-19 cells were pretreated with 17-β 
estradiol 20-160 nM for 6 h and then 
stressed with 5 μM active amyloid-β1-42 for 
24 h. Scrambled amyloid-β42-1 and 
equivalent volume DMSO solutions were 
used as negative controls. Cell viability 
(MTT Assay), reactive oxygen species 
(ROS) production (H2DCFDA Assay), and 
mitochondrial membrane potential (JC-1 
Assay) were assessed. Statistical analysis 
was performed by GraphPad Prism software. 
Statistical significance was determined at 
P42-1. 
RESULTS: 
ARPE-19 cells stressed with 5 μM amyloid-
β1-42 had a significant decrease in cell 
viability (P = 0.0007), which was not 
reversed by pretreatment with 20 and 40 nM 
estradiol. The 5 μM active amyloid-β1-42 did 
not alter the levels of ROS or mitochondrial 
membrane potential compared to the 
scrambled amyloid-b42-1. In addition, 
pretreatment with 20-160 nM estradiol did 
not significantly decrease ROS production 
or increase mitochondrial membrane 
potential in amyloid-b1-42 treated cultures. 
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CONCLUSION: Amyloid-β1-42 decreases 
ARPE-19 cell viability but not through 
mechanisms of ROS production or by 
affecting the mitochondrial membrane 
potential. Although estradiol has been 
shown to be protective on the retina when 
stressed with light or high glucose-induced 
damage, our findings demonstrate that with 
amyloid-β1-42-induced damage, the estradiol 
was unable to prevent RPE death 
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